Alan Wake 2's critical success caused Remedy shares to jump by 20%
Remedy Entertainment recently released the long-awaited Alan Wake 2 to overwhelming critical acclaim, causing the company's stock price to nearly reach a 17-month high.
The details:
As reported by Game World Observer, Remedy's share price reached a high of €29.40 on October 27 following the release of Alan Wake 2, and has since dropped to €29.15 at the time of writing. This high was 20% greater than the previous day, and it was the company's best since May 27, 2022, when its share price reached €30.20.
The 13-year wait between the original game and its sequel appears to have paid off, as Alan Wake 2 has received universal acclaim for its story, visuals, and twist on classic third-person survival horror gameplay by adding detective elements. Players can play as both the titular character and FBI agent Saga Anderson as she attempts to escape from a horror story written by Wake.
Despite the game's release, Remedy is still hard at work on remakes of the first two Max Payne titles, a sequel and multiplayer spin-off to Control, and a new PvE shooter codenamed Vanguard in collaboration with Tencent. All of the projects appear to be in the proof-of-concept stage, so we'll have to wait a while for further details.
More gaming news:
Gameloft has announced that Disney Dreamlight Valley will no longer release as a free-to-play title when it leaves early access in December, instead carrying a $39.99 price tag for its base edition. The title will continue to receive free content updates, but its microtransactions will remain.
Square Enix has released a new trailer for its mobile spin-off, Kingdom Hearts: Missing Link. The game will be released in 2024, with a closed beta coming to iOS next month and an Android test following in January.
